Mayank Mamtani
Stock Analyst at B. Riley Securities
(4.60)
# 248
Out of 5,005 analysts
135
Total ratings
50%
Success rate
41.49%
Average return
Main Sectors:
Stocks Rated by Mayank Mamtani
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| HROW Harrow | Reiterates: Buy | $70 → $74 | $45.43 | +62.89% | 4 | Oct 1, 2025 | |
| MDGL Madrigal Pharmaceuticals | Maintains: Buy | $460 → $560 | $443.01 | +26.41% | 13 | Sep 29, 2025 | |
| NKTR Nektar Therapeutics | Maintains: Buy | $85 → $105 | $60.55 | +73.41% | 3 | Sep 23, 2025 | |
| CYTK Cytokinetics | Maintains: Buy | $74 → $80 | $56.97 | +40.42% | 4 | Sep 22, 2025 | |
| TGTX TG Therapeutics | Maintains: Buy | $53 → $55 | $36.71 | +49.84% | 14 | Sep 17, 2025 | |
| TBPH Theravance Biopharma | Initiates: Buy | $28 | $14.41 | +94.31% | 1 | Sep 12, 2025 | |
| ACTU Actuate Therapeutics | Initiates: Buy | $20 | $6.98 | +186.53% | 1 | Aug 26, 2025 | |
| ALT Altimmune | Maintains: Buy | $20 → $18 | $3.91 | +360.36% | 10 | Aug 13, 2025 | |
| MNOV MediciNova | Maintains: Buy | $6 → $5 | $1.28 | +290.63% | 2 | Jun 16, 2025 | |
| MGNX MacroGenics | Maintains: Neutral | $5 → $3 | $1.78 | +68.54% | 2 | May 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $2.5 → $2 | $0.36 | +453.17% | 6 | Mar 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $11 → $20 | $9.88 | +102.43% | 3 | Mar 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $4 → $3 | $1.69 | +77.51% | 2 | Mar 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $38 → $35 | $15.42 | +126.98% | 2 | Mar 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $51 → $38 | $36.12 | +5.20% | 7 | Feb 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $109 → $96 | $29.72 | +223.01% | 2 | Feb 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $1 → $1.5 | $1.55 | -3.23% | 3 | Dec 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $23 → $26 | $9.46 | +174.84% | 19 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $33 | $23.23 | +42.06% | 1 | Sep 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $140 | $15.78 | +787.20% | 1 | Oct 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $210 → $90 | $3.48 | +2,486.21% | 5 | Apr 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $160 | $4.14 | +3,764.73% | 1 | Mar 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $11 → $5 | $1.92 | +160.42% | 3 | Aug 19, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $58 → $44 | $3.63 | +1,112.12% | 4 | Aug 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $120 → $90 | $2.75 | +3,172.73% | 4 | Jul 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $14 → $7 | $2.08 | +236.54% | 3 | May 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $9,750 → $4,500 | $1.58 | +284,710.13% | 3 | Jan 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $5,000 → $2,700 | $1.95 | +138,361.54% | 2 | Nov 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $138 → $77 | $22.56 | +241.31% | 2 | Jan 15, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $1,980 → $1,440 | $1.57 | +91,619.75% | 3 | May 22, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $8 → $4 | $4.33 | -7.62% | 2 | Apr 3, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $47 → $39 | $104.83 | -62.80% | 2 | Mar 18, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $43 → $34 | $4.08 | +733.66% | 1 | Mar 13, 2020 |
Harrow
Oct 1, 2025
Reiterates: Buy
Price Target: $70 → $74
Current: $45.43
Upside: +62.89%
Madrigal Pharmaceuticals
Sep 29, 2025
Maintains: Buy
Price Target: $460 → $560
Current: $443.01
Upside: +26.41%
Nektar Therapeutics
Sep 23, 2025
Maintains: Buy
Price Target: $85 → $105
Current: $60.55
Upside: +73.41%
Cytokinetics
Sep 22, 2025
Maintains: Buy
Price Target: $74 → $80
Current: $56.97
Upside: +40.42%
TG Therapeutics
Sep 17, 2025
Maintains: Buy
Price Target: $53 → $55
Current: $36.71
Upside: +49.84%
Theravance Biopharma
Sep 12, 2025
Initiates: Buy
Price Target: $28
Current: $14.41
Upside: +94.31%
Actuate Therapeutics
Aug 26, 2025
Initiates: Buy
Price Target: $20
Current: $6.98
Upside: +186.53%
Altimmune
Aug 13, 2025
Maintains: Buy
Price Target: $20 → $18
Current: $3.91
Upside: +360.36%
MediciNova
Jun 16, 2025
Maintains: Buy
Price Target: $6 → $5
Current: $1.28
Upside: +290.63%
MacroGenics
May 20, 2025
Maintains: Neutral
Price Target: $5 → $3
Current: $1.78
Upside: +68.54%
Mar 27, 2025
Maintains: Buy
Price Target: $2.5 → $2
Current: $0.36
Upside: +453.17%
Mar 19, 2025
Reiterates: Buy
Price Target: $11 → $20
Current: $9.88
Upside: +102.43%
Mar 14, 2025
Maintains: Buy
Price Target: $4 → $3
Current: $1.69
Upside: +77.51%
Mar 5, 2025
Reiterates: Buy
Price Target: $38 → $35
Current: $15.42
Upside: +126.98%
Feb 14, 2025
Reiterates: Buy
Price Target: $51 → $38
Current: $36.12
Upside: +5.20%
Feb 7, 2025
Reiterates: Buy
Price Target: $109 → $96
Current: $29.72
Upside: +223.01%
Dec 19, 2024
Upgrades: Buy
Price Target: $1 → $1.5
Current: $1.55
Upside: -3.23%
Oct 10, 2024
Reiterates: Buy
Price Target: $23 → $26
Current: $9.46
Upside: +174.84%
Sep 19, 2024
Initiates: Buy
Price Target: $33
Current: $23.23
Upside: +42.06%
Oct 13, 2023
Initiates: Buy
Price Target: $140
Current: $15.78
Upside: +787.20%
Apr 10, 2023
Maintains: Buy
Price Target: $210 → $90
Current: $3.48
Upside: +2,486.21%
Mar 29, 2023
Reiterates: Buy
Price Target: $160
Current: $4.14
Upside: +3,764.73%
Aug 19, 2022
Downgrades: Neutral
Price Target: $11 → $5
Current: $1.92
Upside: +160.42%
Aug 11, 2022
Maintains: Buy
Price Target: $58 → $44
Current: $3.63
Upside: +1,112.12%
Jul 14, 2022
Maintains: Buy
Price Target: $120 → $90
Current: $2.75
Upside: +3,172.73%
May 24, 2022
Downgrades: Neutral
Price Target: $14 → $7
Current: $2.08
Upside: +236.54%
Jan 24, 2022
Maintains: Buy
Price Target: $9,750 → $4,500
Current: $1.58
Upside: +284,710.13%
Nov 30, 2021
Maintains: Buy
Price Target: $5,000 → $2,700
Current: $1.95
Upside: +138,361.54%
Jan 15, 2021
Downgrades: Neutral
Price Target: $138 → $77
Current: $22.56
Upside: +241.31%
May 22, 2020
Downgrades: Neutral
Price Target: $1,980 → $1,440
Current: $1.57
Upside: +91,619.75%
Apr 3, 2020
Maintains: Buy
Price Target: $8 → $4
Current: $4.33
Upside: -7.62%
Mar 18, 2020
Maintains: Buy
Price Target: $47 → $39
Current: $104.83
Upside: -62.80%
Mar 13, 2020
Maintains: Buy
Price Target: $43 → $34
Current: $4.08
Upside: +733.66%